<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d2 20140930//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id><journal-title-group><journal-title>BMC Cancer</journal-title></journal-title-group><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25109220</article-id><article-id pub-id-type="publisher-id">5015</article-id><article-id pub-id-type="doi">10.1186/1471-2407-14-583</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Elevated levels of plasma D-dimer predict a worse outcome in patients with nasopharyngeal carcinoma</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Chen</surname><given-names>Wen-Hui</given-names></name><address><email>chenwh@sysucc.org.cn</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Tang</surname><given-names>Lin-Quan</given-names></name><address><email>tanglq@sysucc.org.cn</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Feng-Wei</given-names></name><address><email>wangfengw@sysucc.org.cn</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Chang-Peng</given-names></name><address><email>lizhp@sysucc.org.cn</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Tian</surname><given-names>Xiao-Peng</given-names></name><address><email>tianxp@sysucc.org.cn</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Xiao-Xia</given-names></name><address><email>huangxiaox@sysucc.org.cn</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Mai</surname><given-names>Shi-Juan</given-names></name><address><email>maishj@sysucc.org.cn</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Liao</surname><given-names>Yi-Ji</given-names></name><address><email>liaoyj@sysucc.org.cn</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Deng</surname><given-names>Hai-Xia</given-names></name><address><email>denghx@sysucc.org.cn</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Qiu-Yan</given-names></name><address><email>chenqy@sysucc.org.cn</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Huai</given-names></name><address><email>liuhuai@sysucc.org.cn</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Lu</given-names></name><address><email>zhanglu@sysucc.org.cn</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Guo</surname><given-names>Shan-Shan</given-names></name><address><email>guoshsh@sysucc.org.cn</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Li-Ting</given-names></name><address><email>liult@sysucc.org.cn</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Yan</surname><given-names>Shu-Mei</given-names></name><address><email>yanshm@sysucc.org.cn</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Chao-Feng</given-names></name><address><email>lichaofeng@sysucc.org.cn</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Jing-Ping</given-names></name><address><email>zhangjp@sysucc.org.cn</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Qing</given-names></name><address><email>liuqing@sysucc.org.cn</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff6"/></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Xue-Wen</given-names></name><address><email>liuxw@sysucc.org.cn</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff7"/></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Li-Zhi</given-names></name><address><email>liulizh@sysucc.org.cn</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff7"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Mai</surname><given-names>Hai-Qiang</given-names></name><address><email>maihq@sysucc.org.cn</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zeng</surname><given-names>Mu-Sheng</given-names></name><address><email>zengmsh@sysucc.org.cn</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Xie</surname><given-names>Dan</given-names></name><address><email>xied@mail.sysu.edu.cn</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><label/>State Key Laboratory of Oncology in South China; Collaborative Innovation Centre for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060 P. R. China </aff><aff id="Aff2"><label/>Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, 510060 P. R. China </aff><aff id="Aff3"><label/>Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, 510060 P. R. China </aff><aff id="Aff4"><label/>Department of Information Technology, Sun Yat-sen University Cancer Center, Guangzhou, 510060 P. R. China </aff><aff id="Aff5"><label/>Department of Clinical Laboratory, Sun Yat-sen University Cancer Center, Guangzhou, 510060 P. R. China </aff><aff id="Aff6"><label/>Department of Statistics and Epidemiology, Sun Yat-sen University Cancer Center, Guangzhou, 510060 P. R. China </aff><aff id="Aff7"><label/>Imaging Diagnostic and Interventional Centre, Sun Yat-sen University Cancer Center, Guangzhou, 510060 P. R. China </aff></contrib-group><pub-date pub-type="epub"><day>10</day><month>8</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>10</day><month>8</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>14</volume><elocation-id>583</elocation-id><history><date date-type="received"><day>6</day><month>5</month><year>2014</year></date><date date-type="accepted"><day>30</day><month>7</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; Chen et al.; licensee BioMed Central Ltd. 2014</copyright-statement><license license-type="open-access"><license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Hemostatic alterations occur during the development of cancer. Plasma D-dimer is a hypercoagulability and fibrinolytic system marker that is increased in patients with various solid tumours. The aim of this study was to evaluate the hemostatic status of nasopharyngeal carcinoma (NPC) patients by assessing plasma D-dimer levels to investigate its value as a prognostic marker.</p></sec><sec><title>Methods</title><p>We retrospectively analysed 717 patients with nasopharyngeal carcinoma, and we applied Cox regression and log-rank tests to assess the association of D-dimer levels with disease-free survival (DFS), distant metastasis-free survival (DMFS), and overall survival (OS). D-dimer levels were measured using a quantitative D-dimer latex agglutination assay.</p></sec><sec><title>Results</title><p>Using the 3rd quartile values (0.8&#x000a0;&#x003bc;g/L) as the optimal cut-offs, we found that patients with high D-dimer levels have a shorter 3-year DFS, (79%, 95%CI (73.1&#x02013;84.9)) vs. (69%, 95%CI (59.2&#x02013;78.8)), DMFS (87%, 95%CI (83.1&#x02013;90.9)) vs. (77%, 95%CI (69.2&#x02013;84.8)), and overall survival (82%, 95%CI (76.1&#x02013;87.9)) vs. (76%, 95%CI (66.2&#x02013;85.8)). Multivariate analysis revealed that pre-treatment D-dimer levels and EBV DNA were significant independent factors for DFS, DMFS, and OS in NPC patients. Subgroup analyses indicated that the plasma D-dimer levels could effectively stratify patient prognosis for early cancer, advanced stage cancer, and patients with EBV DNA &#x02265;4000 copies/ml.</p></sec><sec><title>Conclusions</title><p>High D-dimer levels were associated with poor disease-free survival, distant metastasis-free survival, overall survival, and increased risk of mortality in NPC patients. Prospective trials are required to assess the prognostic value of D-dimer levels.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/1471-2407-14-583) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Nasopharyngeal carcinoma</kwd><kwd>D-dimer</kwd><kwd>Survival</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Nasopharyngeal carcinoma (NPC) is one of the most common malignancies in southern China, southeastern Asia, and northern Africa. The lowest prevalence of NPC is found in white populations from Europe and the United States [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. Radiotherapy regimens are currently the primary treatment strategy for NPC patients. Although the TNM staging system [<xref ref-type="bibr" rid="CR4">4</xref>] is currently the most powerful prognostic factor for NPC, patients with the same stage and similar treatment regimens have variable clinical outcomes. The expression of several specific biological markers have been used to provide additional prognostic information for NPC patients, including epidermal growth factor receptor [<xref ref-type="bibr" rid="CR5">5</xref>], serum lactate dehydrogenase (LDH) [<xref ref-type="bibr" rid="CR6">6</xref>], C-reactive protein (CRP) [<xref ref-type="bibr" rid="CR7">7</xref>], and plasma Epstein-Barr virus DNA (EBV DNA) [<xref ref-type="bibr" rid="CR8">8</xref>]. Several studies have investigated pre-treatment EBV DNA, which is used for disease monitoring and prognosis prediction in the clinic [<xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>].</p><p>Several studies have suggested an association between a more aggressive cancer phenotype and hypercoagulability [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Interestingly, in the absence of venous thromboembolism (VTE), the systemic activation of blood coagulation and procoagulant changes in the hemostatic system are frequently been observed in cancer patients [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Patients with cancer and hypercoagulation have a higher risk of venous thrombosis and a poor prognosis [<xref ref-type="bibr" rid="CR15">15</xref>]. It has been reported that many increased or decreased coagulation factors contribute to cancer growth, progression and metastasis [<xref ref-type="bibr" rid="CR16">16</xref>]. The plasma D-dimer is a stable end product of fibrin degradation, and it is a useful biomarker for predicting venous thromboembolism (VTE) in cancer patients [<xref ref-type="bibr" rid="CR17">17</xref>]. Increased D-dimer levels are related to tumour stage, tumour prognosis and lymph node involvement. Additionally, D-dimer levels are a negative prognostic indicator for several malignancies, including breast [<xref ref-type="bibr" rid="CR18">18</xref>], colorectal [<xref ref-type="bibr" rid="CR19">19</xref>], lung [<xref ref-type="bibr" rid="CR20">20</xref>], and prostate cancer [<xref ref-type="bibr" rid="CR21">21</xref>]. Elevated D-dimer levels may reflect multifactorial interactions between carcinoma growth and the hemostatic-fibrinolytic system in malignancy. However, the clinical significance of D-dimer in nasopharyngeal carcinoma has not been established.</p><p>The purpose of this study was to analyse the prognostic value of plasma D-dimer levels in patients with NPC and evaluate the correlation between pre-treatment plasma D-dimer levels and clinical-pathological parameters. The results of our study will help predict NPC progression in patients and provide information for further treatment.</p></sec><sec id="Sec2" sec-type="methods"><title>Methods</title><sec id="Sec3"><title>Patient selection</title><p>The principal inclusion criteria were as follows: (1) biopsy-proven primary NPC, no radiotherapy, chemotherapy, or oncologic surgery history, and an ECOG of 0 to 2; (2) patient age &#x02265;18&#x000a0;years; (3) adequate hematologic, renal, and hepatic function (white blood cell count of&#x02009;&#x02265;&#x02009;4000/&#x003bc;&#x000a0;L, platelet count of &#x02265;100000/UL, serum creatinine clearance&#x02009;&#x02265;&#x02009;50&#x000a0;mL/min, total serum bilirubin concentration&#x02009;&#x0003c;&#x02009;1.5&#x000a0;mg/dL); and (4) available follow-up data. The following exclusion criteria were used for our study: (1) patients who had a history of venous thrombosis or anticoagulation therapy within 3&#x000a0;months before treatment; (2) patients with previous or coexisting cancer other than NPC; (3) pregnancy and lactation; or (4) stroke or neurosurgery within 6&#x000a0;months.</p><p>Between January 2008 and December 2011, a total of 717 consecutive non-distant-metastatic NPC patients (average age of 47, ranging from 29 to 71 years old) were enrolled at Sun Yat-sen University Cancer Center (Guangzhou, China). During the same time period, 126 healthy volunteers (average age of 45, ranging from 19 to 75 years old) who submitted to D-dimer testing as part of a routine physical examination in our hospital were enrolled as the control group. This retrospective study was approved by the Clinical Research Ethics Committee of the Sun Yat-sen University Cancer Center, and all the participants provided written informed consent before treatment.</p><p>The routine staging patient work-up included the following clinical examinations of the head and neck region: magnetic resonance imaging scans from the suprasellar cistern to the collarbone, fibre optic nasopharyngoscopy, chest radiography, abdominal sonography, whole-body bone scan or whole body FDG PET/CT. All patients were restaged according to the seventh American Joint Committee on Cancer (AJCC) TNM staging manual. All clinical records and magnetic resonance images were independently reviewed by 2 radiologists (X.W.L and L.Z.L.) to minimise heterogeneity in restaging. Before treatment, the following baseline clinical data were collected from the medical records and information system at the study institute: sex, age, WBC counts, neutrophil counts, haemoglobin (HGB), platelet counts, LDH, CRP, hereditary NPC, smoking status, PS by Eastern Cooperative Oncology Group (ECOG), and the presence of concurrent diseases, such as cardiovascular disease, diabetes and chronic hepatitis.</p><sec id="Sec4"><title>Treatment delivery</title><p>One hundred and sixty-seven (23.3%) patients were treated with conventional two-dimensional (2D-CRT) or three-dimensional conformal radiotherapy (3D-CRT), and the remaining 550 (76.7%) patients were treated with intensity-modulated radiotherapy (IMRT). Details of the radiotherapy techniques used at the Sun Yat-sen University Cancer Center were reported in a previous study [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Six hundred and forty (91.3%) patients with stage II&#x02013;IV disease received concurrent platinum-based chemotherapy.</p><p>A stratified multi-therapeutic protocol was used to treat patients. Radiation therapy alone was used for stage I disease, and radiation with concurrent platinum-based chemotherapy was used to treat stage II disease [<xref ref-type="bibr" rid="CR24">24</xref>]. Concurrent chemoradiotherapy, with or without neoadjuvant or adjuvant chemotherapy, was used for advanced-stage disease (stages III and IV). Neoadjuvant or adjuvant chemotherapy consisted of cisplatin with 5-fluorouracil or cisplatin with taxane administered every 3&#x000a0;weeks for 2 or 3&#x000a0;cycles [<xref ref-type="bibr" rid="CR25">25</xref>]. The concurrent chemotherapy regimen consisted of cisplatin given on weeks 1, 4, and 7 of RT, or weekly cisplatin. All the patients at the study institution were treated according to the principle of treatment for NPC patients at Sun Yat-sen University Cancer Center, Guangzhou, China.</p></sec></sec><sec id="Sec5"><title>D-dimer evaluation</title><p>A 3&#x000a0;mL fasting blood sample was collected before treatment of NPC patients and on the day of physical examination for the healthy volunteers. The sample was processed within 3&#x000a0;hours of collection, and the plasma was stored at &#x02212;70 to &#x02212;80&#x000b0;C until analysis. D-dimer values were measured by a latex-enhanced immunoturbidimetric assay (Sekisui Medical Co., Ltd., Tokyo, Japan) using a Sysmex CA 7000 (Sysmex Corp., Kobe, Japan) analyser in the clinical hospital laboratory. The results were obtained using a standard curve prepared according to the manufacturer&#x02019;s instructions, and the inter-assay imprecision (coefficient of variation) was&#x02009;&#x0003c;&#x02009;10%.</p></sec><sec id="Sec6"><title>EBV DNA, VCA-IgA, and EA-IgA measurement</title><p>As described in previous studies [<xref ref-type="bibr" rid="CR26">26</xref>&#x02013;<xref ref-type="bibr" rid="CR28">28</xref>], patient plasma EBV DNA concentrations were routinely measured by q-PCR before treatment. A cut-off level of 4000 copies/ml was chosen to define low and high EBV DNA levels because this threshold has previously been shown to be prognostic in NPC patients using the same measurement system [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. EBV-specific VCA/IgA antibodies and EBV-specific EA/IgA antibodies were measured using a previously described immunoenzymatic assay [<xref ref-type="bibr" rid="CR30">30</xref>].</p><sec id="Sec7"><title>Clinical outcomes assessment and patient follow-up</title><p>The primary endpoint of our study was disease-free survival (DFS). The secondary endpoints were distant metastasis-free survival (DMFS) and overall survival (OS). We calculated DFS from the date of the first NPC diagnosis to the date of the first relapse at any site, death from any cause or the date of the last follow-up visit. DMFS was calculated from the date of the first NPC diagnosis to the date of distant relapse or patient censoring at the date of the last follow-up. OS was calculated from the date of the first NPC diagnosis to the date of death from any cause or patient censoring at the date of the last follow-up. After treatment was completed, patients were evaluated at 3-month intervals for the first 3&#x000a0;years and every 6&#x000a0;months thereafter.</p></sec></sec><sec id="Sec8"><title>Statistical analysis</title><p>The characteristics of the patients were divided into quartiles and described by median values and the 25th-75th percentiles (due to non-normally distributed continuous variables). Mann&#x02013;Whitney U-tests were used to compare continuous variables in different subgroups. The Spearman correlation test was used to examine the association between D-dimer levels and other variables. Survival curves were calculated by the Kaplan-Meier method, and univariate analyses were performed using the log-rank test. Variables that reached a p-value of&#x02009;&#x02264;&#x02009;0.05 in the univariate analysis were entered into multivariate analyses. All statistical calculations were performed using SPSS 17.0 for Windows (Chicago, IL), and a P&#x02009;&#x0003c;&#x02009;0.05 was considered statistically significant.</p></sec></sec><sec id="Sec9" sec-type="results"><title>Results</title><sec id="Sec10"><title>Baseline characteristics and distribution of D-dimer level in the study population and subgroups</title><p>The pretreatment characteristics of the 717 NPC patients are listed in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. The median follow-up was 31&#x000a0;months (IQR, 24&#x02013;42). Forty-eight patients developed locoregional recurrences, and 85 patients developed distant metastases. Of these patients, 16 patients had both local and distant metastases. The plasma D-dimer level was higher in NPC patients than healthy volunteers (P&#x02009;&#x0003c;&#x02009;0.001, Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>), with the values of 0.50 (25th-75th percentile: 0.3-0.8) and 0.4 ug/mL (25th-75th percentile: 0.3-0.5), respectively. The median D-dimer level was higher in patients with distant metastasis compared to patients without distant metastasis (P&#x02009;=&#x02009;0.002, Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>), with values of 0.60 (25th-75th percentile: 0.4-1.0) and 0.50 (25th-75th percentile: 0.3-0.7), respectively. The D-dimer level was higher in patients with plasma EBVDNA&#x02009;&#x02265;&#x02009;4000 copies than in patients with EBVDNA&#x02009;&#x0003c;&#x02009;4000 copies (P&#x02009;=&#x02009;0.002, Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>), with values of 0.50 (25th-75th percentile: 0.3-0.9) and 0.50 (25th-75th percentile: 0.3-0.7), respectively. Patients who died during the observation period had significantly higher D-dimer levels at baseline than patients who were alive at the end of the study or the last follow-up: 0.6 (25th-75th percentile: 0.4-0.925) and 0.5 (25th-75th percentile: 0.3-0.7), respectively (P&#x02009;=&#x02009;0.002, Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). A Spearman correlation analysis further demonstrated that plasma D-dimer levels correlated with age, serum CRP level, LDH level, EBV DNA level, tumour TNM stage, and distant metastasis (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1).<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Patient demographics and clinical characteristics</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Characteristic</th><th>Median (25th-75th percentile) or No. (%)</th><th>Median (25th-75th percentile) or No. (%)</th></tr><tr><th/><th>NPC patients (n&#x02009;=&#x02009;717)</th><th>Control (n&#x02009;=&#x02009;126)</th></tr></thead><tbody><tr><td>Age at study entry</td><td align="center">47 (39&#x02013;47)</td><td align="center">45 (39&#x02013;53)</td></tr><tr><td>Sex</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;Male</td><td align="center">533 (74.3)</td><td align="center">102 (81)</td></tr><tr><td>&#x02003;Female</td><td align="center">184 (25.7)</td><td align="center">24 (19.0)</td></tr><tr><td>D-dimer</td><td align="center">0.50 ug/mL (0.3-0.8)</td><td align="center">0.40 ug/mL (0.3-0.5)</td></tr><tr><td>Histology, WHO type</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;III</td><td align="center">690 (96.2)</td><td align="center"/></tr><tr><td>&#x02003;II</td><td align="center">27 (3.8)</td><td align="center"/></tr><tr><td>ECOG</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;0-1</td><td align="center">712 (99.3)</td><td align="center"/></tr><tr><td>&#x02003;2</td><td align="center">5 (0.7)</td><td align="center"/></tr><tr><td>Clinical stage</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;I</td><td align="center">16 (2.2)</td><td align="center"/></tr><tr><td>&#x02003;II</td><td align="center">80 (11.2)</td><td align="center"/></tr><tr><td>&#x02003;III</td><td align="center">416 (58.0)</td><td align="center"/></tr><tr><td>&#x02003;IV</td><td align="center">205 (28.6)</td><td align="center"/></tr><tr><td>Tumour stage</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;T1</td><td align="center">54 (7.5)</td><td align="center"/></tr><tr><td>&#x02003;T2</td><td align="center">128 (17.9)</td><td align="center"/></tr><tr><td>&#x02003;T3</td><td align="center">367 (51.2)</td><td align="center"/></tr><tr><td>&#x02003;T4</td><td align="center">168 (23.4)</td><td align="center"/></tr><tr><td>Node stage</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;N0</td><td align="center">112 (15.6)</td><td align="center"/></tr><tr><td>&#x02003;N1</td><td align="center">273 (38.1)</td><td align="center"/></tr><tr><td>&#x02003;N2</td><td align="center">277 (38.6)</td><td align="center"/></tr><tr><td>&#x02003;N3</td><td align="center">55 (7.7)</td><td align="center"/></tr><tr><td>Treatment</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;Radiotherapy</td><td align="center">75 (10.5)</td><td align="center"/></tr><tr><td>&#x02003;Chemotherapy and radiotherapy</td><td align="center">642 (89.5)</td><td align="center"/></tr><tr><td>Radiotherapy technique</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;2DRT/3DCRT</td><td align="center">167 (23.3)</td><td align="center"/></tr><tr><td>&#x02003;IMRT</td><td align="center">550 (76.7)</td><td align="center"/></tr><tr><td>EBVDNA</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;Low DNA</td><td align="center">411 (57.3)</td><td align="center"/></tr><tr><td>&#x02003;High DNA</td><td align="center">306 (42.7)</td><td align="center"/></tr><tr><td>VCA-IgA</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x0003c;1:80</td><td align="center">223 (31.1)</td><td align="center"/></tr><tr><td>&#x02003;&#x02265;1:80</td><td align="center">494 (68.9)</td><td align="center"/></tr><tr><td>EA-IgA</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x0003c;1:10</td><td align="center">315 (43.9)</td><td align="center"/></tr><tr><td>&#x02003;&#x02265;1:10</td><td align="center">402 (56.1)</td><td align="center"/></tr><tr><td>LDH, U/L</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x0003c; 167</td><td align="center">353 (49.2)</td><td align="center"/></tr><tr><td>&#x02003;&#x02265;167</td><td align="center">364 (50.8)</td><td align="center"/></tr><tr><td>CRP, mg/L</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x0003c; 1.61</td><td align="center">359 (50.1)</td><td align="center"/></tr><tr><td>&#x02003;&#x02265;1.61</td><td align="center">358 (49.9)</td><td align="center"/></tr><tr><td>WBC, 109/L</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x0003c; 6.7</td><td align="center">362 (50.5)</td><td align="center"/></tr><tr><td>&#x02003;&#x02265;6.7</td><td align="center">355 (49.5)</td><td align="center"/></tr><tr><td>Neutrophil, 109/L</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x0003c; 4.0</td><td align="center">359 (50.2)</td><td align="center"/></tr><tr><td>&#x02003;&#x02265;4.0</td><td align="center">358 (49.8)</td><td align="center"/></tr><tr><td>HGB, g/L</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x0003c; 143.8</td><td align="center">359 (50.1)</td><td align="center"/></tr><tr><td>&#x02003;&#x02265; 143.8</td><td align="center">358 (49.9)</td><td align="center"/></tr><tr><td>PLT, 109/L</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;&#x0003c; 227</td><td align="center">359 (50.1)</td><td align="center"/></tr><tr><td>&#x02003;&#x02265;227</td><td align="center">358 (49.9)</td><td align="center"/></tr><tr><td>Smoking</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;yes</td><td align="center">259 (63.9)</td><td align="center"/></tr><tr><td>&#x02003;no</td><td align="center">458 (36.1)</td><td align="center"/></tr><tr><td>Chronic HBV Infection</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;yes</td><td align="center">57 (7.9)</td><td align="center"/></tr><tr><td>&#x02003;no</td><td align="center">660 (92.1)</td><td align="center"/></tr><tr><td>Cardiovascular disease</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;yes</td><td align="center">61 (8.5)</td><td align="center"/></tr><tr><td>&#x02003;no</td><td align="center">656 (91.5)</td><td align="center"/></tr><tr><td>Diabetes mellitus</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;yes</td><td align="center">22 (3.1)</td><td align="center"/></tr><tr><td>&#x02003;no</td><td align="center">695 (96.9)</td><td align="center"/></tr><tr><td>Family history of NPC</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;yes</td><td align="center">61 (8.5)</td><td align="center"/></tr><tr><td>&#x02003;no</td><td align="center">656 (91.5)</td><td align="center"/></tr><tr><td>&#x02003;Median follow-up (months)</td><td align="center">31 (24&#x02013;44)</td><td align="center"/></tr><tr><td>Outcome features</td><td align="center"/><td align="center"/></tr><tr><td>Progression</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;yes</td><td align="center">118 (16.5)</td><td align="center"/></tr><tr><td>&#x02003;no</td><td align="center">599 (83.5)</td><td align="center"/></tr><tr><td>Distant metastasis</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;yes</td><td align="center">85 (11.9)</td><td align="center"/></tr><tr><td>&#x02003;no</td><td align="center">632 (88.1)</td><td align="center"/></tr><tr><td>Localregional recurrence</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;yes</td><td align="center">48 (6.7)</td><td align="center"/></tr><tr><td>&#x02003;no</td><td align="center">669 (93.3)</td><td align="center"/></tr><tr><td>Deaths</td><td align="center"/><td align="center"/></tr><tr><td>&#x02003;yes</td><td align="center">94 (13.1)</td><td align="center"/></tr><tr><td>&#x02003;no</td><td align="center">623 (86.9)</td><td align="center"/></tr></tbody></table><table-wrap-foot><p>
<italic>Abbreviations</italic>: <italic>ECOG</italic>&#x02009;&#x02009;Eastern Cooperative Oncology Group, <italic>2DRT</italic>&#x02009;&#x02009;two-dimensional radiotherapy, <italic>3DCRT</italic>&#x02009;&#x02009;three-dimensional conformal radiotherapy, <italic>IMRT</italic>&#x02009;&#x02009;intensity-modulated radiotherapy, Low DNA denotes a low EBV DNA level of &#x0003c;4000 copies/ml, High DNA denotes a high EBV DNA level of &#x02265;4000 copies/ml, <italic>VCA</italic>&#x02009;&#x02009;viral capsid antigen. <italic>IgA</italic>&#x02009;&#x02009;immunoglobulin A, <italic>EA</italic>&#x02009;&#x02009;early antigen, <italic>LDH</italic>&#x02009;&#x02009;Serum Lactate Dehydrogenase Levels, <italic>CRP</italic>&#x02009;&#x02009;high-sensitivity C-reactive protein, <italic>WBC</italic>&#x02009;&#x02009;White blood cell, <italic>HGB</italic>&#x02009;&#x02009;haemoglobin, <italic>PLT</italic>&#x02009;&#x02009;platelet, <italic>NPC</italic>&#x02009;&#x02009;nasopharyngeal carcinoma.</p></table-wrap-foot></table-wrap><fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>Plasma D-dimer levels are expressed as the median and 5%-95% percentile in patients with nasopharyngeal carcinoma according to different variables. (A)</bold> Healthy volunteers versus nasopharyngeal carcinoma patients; <bold>(B)</bold> Nasopharyngeal carcinoma with distant metastasis after treatment versus non-distant metastasis (P&#x02009;=&#x02009;0.002); <bold>(C)</bold> Non-survivors versus survivors (P&#x02009;=&#x02009;0.002); <bold>(D)</bold> High DNA (&#x02265;4000 copies/ml) versus low DNA (&#x0003c;4000 copies/ml) (P&#x02009;=&#x02009;0.002).</p></caption><graphic xlink:href="12885_2014_5015_Fig1_HTML" id="d30e1408"/></fig></p></sec><sec id="Sec11"><title>D-dimer levels and probability of survival</title><p>For the Kaplan-Meier analysis, patients were categorised into the following four groups according to their D-dimer levels: the1st group (D-dimer levels ranging from minimum to 1st quartile of D-dimer levels in the total cohort population: 0.0-0.3&#x000a0;&#x003bc;g/mL), 2nd group (D-dimer levels from 1st quartile to 2nd quartile: 0.3-0.5&#x000a0;&#x003bc;g/mL), 3rd group (D-dimer levels from 2nd quartile to 3rd quartile: 0.5-0.8&#x000a0;&#x003bc;g/mL) and 4th group (D-dimer levels from 3rd quartile to maximum: 0.8-37.2&#x000a0;&#x003bc;g/mL). Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S1 shows the Kaplan-Meier estimates for DFS, DMFS and OS according to D-dimer levels. Elevated D-dimer levels were significantly associated with shorter DFS, DMFS and OS (log-rank trend test: P&#x02009;&#x0003c;&#x02009;0.001).</p><p>Using the 1st group as a reference, the unadjusted hazard ratio (HR) for DFS, DMFS, and OS of the top quartiles were 2.26 (95% CI, 1.38-3.70), 2.99 (95% CI, 1.63-5.48), and 3.06 (95% CI, 1.70-5.51), respectively. A similar trend of adjusted HR was observed for DFS, DMFS and OS. HRs and 95% CIs comparing quartiles of D-dimer for disease-free, distant metastasis and overall survival are detailed in Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2. The patients were divided into two groups based on whether the D-dimer level was above or below the top quartiles (0.8&#x000a0;&#x003bc;g/L). Patients with high D-dimer levels had a shorter 3-year DFS, (79%, 95%CI (73.1&#x02013;84.9)) vs. (69%, 95%CI (59.2&#x02013;78.8)), DMFS (87%, 95%CI (83.1&#x02013;90.9)) vs. (77%, 95%CI (69.2&#x02013;84.8)), and overall survival (82%, 95%CI (76.1&#x02013;87.9)) vs. (76%, 95%CI (66.2&#x02013;85.8)) (Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Figure 2</label><caption><p>
<bold>Kaplan-Meier curves of disease-free survival (A), distant metastasis-free survival (B), and overall survival (C) of the entire NPC population according to pre-treatment D-dimer levels (n = 717).</bold>
</p></caption><graphic xlink:href="12885_2014_5015_Fig2_HTML" id="d30e1436"/></fig></p></sec><sec id="Sec12"><title>Univariate and multivariate analyses of prognostic factors</title><p>As shown in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>, using 0.8 ug/L as a cut-off value, the hazard ratios (HRs) and 95% CIs estimated from Cox regression models indicated that the D-dimer level was strongly associated with DFS, DMFS, and OS (HR, 1.88; 95% CI, 1.28 to 2.77), (HR, 2.16; 95%CI, 1.38 to 3.36) and (HR, 1.98; 95%CI, 1.29 to 3.04), respectively. In addition to elevated D-dimer levels, the UICC TNM classification, high EBV DNA and elevated CRP levels (1.61&#x000a0;mg/L) were significantly associated with DFS, DMFS, and OS.<table-wrap id="Tab2"><label>Table 2</label><caption><p>
<bold>Univariate Cox proportional hazards regression analysis</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Characteristic</th><th colspan="3">DFS (n&#x02009;=&#x02009;717)</th><th colspan="3">DMFS (n&#x02009;=&#x02009;717)</th><th colspan="3">OS (n&#x02009;=&#x02009;717)</th></tr><tr><th/><th>HR</th><th>95% CI</th><th>
<bold><italic>P</italic></bold>
</th><th>HR</th><th>95% CI</th><th>
<bold><italic>P</italic></bold>
</th><th>HR</th><th>95% CI</th><th>
<bold><italic>P</italic></bold>
</th></tr></thead><tbody><tr><td align="center">Age, (&#x02265;47 vs.&#x02009;&#x0003c;&#x02009;47&#x000a0;years)</td><td align="center">0.73</td><td align="center">0.51 to 1.06</td><td align="center">0.100</td><td align="center">0.87</td><td align="center">0.56 to 1.33</td><td align="center">0.517</td><td align="center">0.85</td><td align="center">0.56 to 1.29</td><td align="center">0.444</td></tr><tr><td align="center">Male vs. Female</td><td align="center">1.08</td><td align="center">0.71 to 1.65</td><td align="center">0.726</td><td align="center">1.48</td><td align="center">0.86 to 2.54</td><td align="center">0.162</td><td align="center">0.92</td><td align="center">0.64 to 1.65</td><td align="center">0.922</td></tr><tr><td align="center">Histology, WHO type (III vs. II)</td><td align="center">0.95</td><td align="center">0.42 to 2.53</td><td align="center">0.949</td><td align="center">0.69</td><td align="center">0.28 to 1.70</td><td align="center">0.689</td><td align="center">1.78</td><td align="center">0.56 to 5.62</td><td align="center">0.328</td></tr><tr><td align="center">ECOG (2 vs. 0&#x02013;1)</td><td align="center">1.10</td><td align="center">0.15 to 7.85</td><td align="center">0.927</td><td align="center">1.05</td><td align="center">0.36 to 6.53</td><td align="center">0.596</td><td align="center">1.25</td><td align="center">0.14 to 8.99</td><td align="center">0.824</td></tr><tr><td align="center">
<bold>Clinical stage (III-IV) vs. (I-II)</bold>
</td><td align="center">
<bold>3.05</bold>
</td><td align="center">
<bold>1.34 to 6.94</bold>
</td><td align="center">
<bold>0.008</bold>
</td><td align="center">
<bold>4.43</bold>
</td><td align="center">
<bold>1.40 to 14.01</bold>
</td><td align="center">
<bold>0.011</bold>
</td><td align="center">
<bold>2.56</bold>
</td><td align="center">
<bold>1.04 to 6.31</bold>
</td><td align="center">
<bold>0.041</bold>
</td></tr><tr><td align="center">
<bold>Tumour stage (T3-4 vs. T1-2)</bold>
</td><td align="center">
<bold>1.47</bold>
</td><td align="center">
<bold>0.93 to 2.31</bold>
</td><td align="center">
<bold>0.100</bold>
</td><td align="center">
<bold>1.65</bold>
</td><td align="center">
<bold>0.94 to 2.88</bold>
</td><td align="center">
<bold>0.08</bold>
</td><td align="center">
<bold>1.32</bold>
</td><td align="center">
<bold>0.80 to 2.18</bold>
</td><td align="center">
<bold>0.286</bold>
</td></tr><tr><td align="center">
<bold>Node stage (N2-3 vs. N0-1)</bold>
</td><td align="center">
<bold>1.72</bold>
</td><td align="center">
<bold>1.19 to 2.48</bold>
</td><td align="center">
<bold>0.004</bold>
</td><td align="center">
<bold>2.19</bold>
</td><td align="center">
<bold>1.40 to 3.42</bold>
</td><td align="center">
<bold>0.001</bold>
</td><td align="center">
<bold>1.75</bold>
</td><td align="center">
<bold>1.16 to 2.66</bold>
</td><td align="center">
<bold>0.008</bold>
</td></tr><tr><td align="center">
<bold>Chemoradiotherapy (yes v no)</bold>
</td><td align="center">
<bold>1.94</bold>
</td><td align="center">
<bold>0.90 to 4.17</bold>
</td><td align="center">
<bold>0.089</bold>
</td><td align="center">
<bold>1.58</bold>
</td><td align="center">
<bold>0.69 to 3.63</bold>
</td><td align="center">
<bold>0.279</bold>
</td><td align="center">
<bold>1.59</bold>
</td><td align="center">
<bold>0.70 to 3.64</bold>
</td><td align="center">
<bold>0.27</bold>
</td></tr><tr><td align="center">
<bold>IMRT vs. 2DRT/3DCRT</bold>
</td><td align="center">
<bold>0.55</bold>
</td><td align="center">
<bold>0.38 to 0.80</bold>
</td><td align="center">
<bold>0.002</bold>
</td><td align="center">
<bold>0.66</bold>
</td><td align="center">
<bold>0.42 to 1.04</bold>
</td><td align="center">
<bold>0.071</bold>
</td><td align="center">
<bold>0.88</bold>
</td><td align="center">
<bold>0.57 to 1.34</bold>
</td><td align="center">
<bold>0.537</bold>
</td></tr><tr><td align="center">High DNA Vs. Low DNA</td><td align="center">2.97</td><td align="center">2.02 to 4.36</td><td align="center">&#x0003c; 0.001</td><td align="center">3.69</td><td align="center">2.30 to 5.91</td><td align="center">&#x0003c; 0.001</td><td align="center">3.50</td><td align="center">2.23 to 5.50</td><td align="center">&#x0003c; 0.001</td></tr><tr><td align="center">
<bold>CRP, mg/L (&#x02265;1.61vs.&#x02009;&#x0003c;&#x02009;1.61)</bold>
</td><td align="center">
<bold>1.43</bold>
</td><td align="center">
<bold>0.99 to 2.06</bold>
</td><td align="center">
<bold>0.055</bold>
</td><td align="center">
<bold>1.83</bold>
</td><td align="center">
<bold>1.18 to 2.84</bold>
</td><td align="center">
<bold>0.007</bold>
</td><td align="center">
<bold>1.87</bold>
</td><td align="center">
<bold>1.23 to 2.85</bold>
</td><td align="center">
<bold>0.003</bold>
</td></tr><tr><td align="center">VCA-IgA (&#x02265;1:80 vs.&#x02009;&#x0003c;&#x02009;1:80)</td><td align="center">1.39</td><td align="center">0.91 to 2.13</td><td align="center">0.127</td><td align="center">1.32</td><td align="center">0.81 to 2.16</td><td align="center">0.267</td><td align="center">0.95</td><td align="center">0.64 to 1.61</td><td align="center">0.952</td></tr><tr><td align="center">EA-IgA (&#x02265;1:10 vs.&#x02009;&#x0003c;&#x02009;1:10)</td><td align="center">1.23</td><td align="center">0.85 to 1.77</td><td align="center">0.282</td><td align="center">1.17</td><td align="center">0.76 to 1.81</td><td align="center">0.477</td><td align="center">0.99</td><td align="center">0.66 to 1.50</td><td align="center">0.977</td></tr><tr><td align="center">
<bold>LDH, U/L (&#x02265;167 vs. &#x0003c; 167)</bold>
</td><td align="center">
<bold>1.41</bold>
</td><td align="center">
<bold>0.98 to 2.04</bold>
</td><td align="center">
<bold>0.064</bold>
</td><td align="center">
<bold>1.67</bold>
</td><td align="center">
<bold>1.07 to 2.59</bold>
</td><td align="center">
<bold>0.002</bold>
</td><td align="center">
<bold>1.38</bold>
</td><td align="center">
<bold>0.92 to 2.08</bold>
</td><td align="center">
<bold>0.125</bold>
</td></tr><tr><td align="center">
<bold>D-dimer, ug/L (&#x02265;0.8 vs.&#x02009;&#x0003c;&#x02009;0.8)</bold>
</td><td align="center">
<bold>1.88</bold>
</td><td align="center">
<bold>1.28 to 2.77</bold>
</td><td align="center">
<bold>0.001</bold>
</td><td align="center">
<bold>2.16</bold>
</td><td align="center">
<bold>1.38 to 3.36</bold>
</td><td align="center">
<bold>0.001</bold>
</td><td align="center">
<bold>1.98</bold>
</td><td align="center">
<bold>1.29 to 3.04</bold>
</td><td align="center">
<bold>0.002</bold>
</td></tr><tr><td align="center">WBC, 109/L (&#x02265;6.7 vs.&#x02009;&#x0003c;&#x02009;6.7)</td><td align="center">1.06</td><td align="center">0.90 to 1.25</td><td align="center">0.753</td><td align="center">1.17</td><td align="center">0.76 to 1.9</td><td align="center">0.481</td><td align="center">1.08</td><td align="center">0.72 to 1.62</td><td align="center">0.709</td></tr><tr><td align="center">Neutrophil, 109/L (&#x02265;4.1 vs.&#x02009;&#x0003c;&#x02009;4.1)</td><td align="center">1.09</td><td align="center">0.76 to 1.56</td><td align="center">0.658</td><td align="center">1.03</td><td align="center">0.67 to 1.57</td><td align="center">0.9</td><td align="center">1.24</td><td align="center">0.82 to 1.87</td><td align="center">0.308</td></tr><tr><td align="center">HGB, g/l (&#x02265;143.8 vs.&#x02009;&#x0003c;&#x02009;143.8)</td><td align="center">0.87</td><td align="center">0.61 to 1.25</td><td align="center">0.463</td><td align="center">0.82</td><td align="center">0.53 to 1.25</td><td align="center">0.35</td><td align="center">0.77</td><td align="center">0.51 to 1.16</td><td align="center">0.207</td></tr><tr><td align="center">PLT, 109/L (&#x02265;227 vs.&#x02009;&#x0003c;&#x02009;227)</td><td align="center">1.13</td><td align="center">0.79 to 1.62</td><td align="center">0.511</td><td align="center">1.08</td><td align="center">0.71 to 1.66</td><td align="center">0.712</td><td align="center">1.23</td><td align="center">0.82 to 1.84</td><td align="center">0.33</td></tr><tr><td align="center">
<bold>Smoking (yes vs. no)</bold>
</td><td align="center">
<bold>1.27</bold>
</td><td align="center">
<bold>0.88 to 1.84</bold>
</td><td align="center">
<bold>0.196</bold>
</td><td align="center">
<bold>1.59</bold>
</td><td align="center">
<bold>1.04 to 2.44</bold>
</td><td align="center">
<bold>0.033</bold>
</td><td align="center">
<bold>1.22</bold>
</td><td align="center">
<bold>0.81 to 1.84</bold>
</td><td align="center">
<bold>0.346</bold>
</td></tr><tr><td align="center">Chronic HBV Infection (yes vs. no)</td><td align="center">1.00</td><td align="center">0.84 to 1.18</td><td align="center">0.953</td><td align="center">1.02</td><td align="center">0.84 to 1.23</td><td align="center">0.881</td><td align="center">0.97</td><td align="center">0.80 to 1.18</td><td align="center">0.969</td></tr><tr><td align="center">cardiovascular disease (yes v no)</td><td align="center">1.16</td><td align="center">0.61 to 2.22</td><td align="center">0.653</td><td align="center">1.28</td><td align="center">0.62 to 2.67</td><td align="center">0.5</td><td align="center">1.64</td><td align="center">0.79 to 3.41</td><td align="center">0.184</td></tr><tr><td align="center">Diabetes mellitus (yes v no)</td><td align="center">0.94</td><td align="center">0.85 to 1.05</td><td align="center">0.286</td><td align="center">0.97</td><td align="center">0.87 to 1.08</td><td align="center">0.592</td><td align="center">0.94</td><td align="center">0.84 to1.05</td><td align="center">0.248</td></tr><tr><td align="center">family history of NPC (yes v no)</td><td align="center">1.14</td><td align="center">0.61 to 2.11</td><td align="center">0.686</td><td align="center">1.13</td><td align="center">0.55 to 2.35</td><td align="center">0.735</td><td align="center">1.14</td><td align="center">0.92 to 1.41</td><td align="center">0.241</td></tr></tbody></table><table-wrap-foot><p>
<italic>Abbreviations</italic>: <italic>ECOG</italic>&#x02009;&#x02009;Eastern Cooperative Oncology Group, <italic>2DRT</italic>&#x02009;&#x02009;two-dimensional radiotherapy, <italic>3DCRT</italic>&#x02009;&#x02009;three-dimensional conformal radiotherapy, <italic>IMRT</italic>&#x02009;&#x02009;intensity-modulated radiotherapy, Low DNA denotes a low EBV DNA level of &#x0003c;4000 copies/ml, High DNA denotes a high EBV DNA level of &#x02265;4000 copies/ml, <italic>VCA</italic>&#x02009;&#x02009;viral capsid antigen. <italic>IgA</italic>&#x02009;&#x02009;immunoglobulin A, <italic>EA</italic>&#x02009;&#x02009;early antigen, <italic>LDH</italic>&#x02009;&#x02009;Serum Lactate Dehydrogenase Levels, <italic>CRP</italic>&#x02009;&#x02009;high-sensitivity C-reactive protein, <italic>WBC</italic>&#x02009;&#x02009;White blood cell, <italic>HGB</italic>&#x02009;&#x02009;haemoglobin, <italic>PLT</italic>&#x02009;&#x02009;platelet, <italic>NPC</italic>&#x02009;&#x02009;nasopharyngeal carcinoma. <italic>DFS</italic>&#x02009;&#x02009;disease-free survival, <italic>DMFS</italic>&#x02009;&#x02009;metastasis-free survival, <italic>OS</italic>&#x02009;&#x02009;overall survival.</p></table-wrap-foot></table-wrap></p><p>Multivariate analysis indicated that elevated D-dimer levels were a highly significant predictor for DFS, DMFS, and OS, independent of EBV DNA level, LDH level, CRP levels, UICC TNM staging, smoking status, and treatment type (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption><p>
<bold>Multivariate Cox proportional hazards regression analysis</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Characteristic</th><th colspan="3">DFS (n&#x02009;=&#x02009;717)</th><th colspan="3">DMFS (n&#x02009;=&#x02009;717)</th><th colspan="3">OS (n&#x02009;=&#x02009;717)</th></tr><tr><th>HR</th><th>95% CI</th><th>
<bold><italic>P</italic></bold>
</th><th>HR</th><th>95% CI</th><th>
<bold><italic>P</italic></bold>
</th><th>HR</th><th>95% CI</th><th>
<bold><italic>P</italic></bold>
</th></tr></thead><tbody><tr><td align="center">Tumour stage (T3-4 vs. T1-2)</td><td align="center">1.23</td><td align="center">0.76 to 1.99</td><td align="center">0.395</td><td align="center">1. 36</td><td align="center">0.76 to 2.45</td><td align="center">0.305</td><td align="center">1.04</td><td align="center">0.61 to 1.79</td><td align="center">0.88</td></tr><tr><td align="center">Node stage (N2-3 vs. N0-1)</td><td align="center">1.14</td><td align="center">0.76 to 1.71</td><td align="center">0.516</td><td align="center">1.43</td><td align="center">0.88 to 2.33</td><td align="center">0.148</td><td align="center">1.08</td><td align="center">0.68 to 1.72</td><td align="center">0.756</td></tr><tr><td align="center">Chemoradiotherapy (yes vs. no)</td><td align="center">1.23</td><td align="center">0.55 to 2.74</td><td align="center">0.621</td><td align="center">0.84</td><td align="center">0.40 to 2.02</td><td align="center">0.7</td><td align="center">0.89</td><td align="center">0.36 to 2.18</td><td align="center">0.793</td></tr><tr><td align="center">IMRT vs. 2DRT/3DCRT</td><td align="center">0.62</td><td align="center">0.42 to 0.90</td><td align="center">0.013</td><td align="center">0.76</td><td align="center">0.48 to 1.21</td><td align="center">0.246</td><td align="center">0.99</td><td align="center">0.64 to 1.52</td><td align="center">0.954</td></tr><tr><td align="center">High DNA vs. Low DNA</td><td align="center">2.41</td><td align="center">1.59 to 3.64</td><td align="center">&#x0003c; 0.001</td><td align="center">2.77</td><td align="center">1.66 to 4.62</td><td align="center">&#x0003c; 0.001</td><td align="center">3.06</td><td align="center">1.87 to 5.02</td><td align="center">&#x0003c; 0.001</td></tr><tr><td align="center">CRP, mg/L (&#x02265;1.61 vs.&#x02009;&#x0003c;&#x02009;1.61)</td><td align="center">1.14</td><td align="center">0.78 to 1.68</td><td align="center">0.495</td><td align="center">1.35</td><td align="center">0.85 to 2.14</td><td align="center">0.21</td><td align="center">1.48</td><td align="center">0.95 to 231</td><td align="center">0.082</td></tr><tr><td align="center">LDH, U/L (&#x02265;167 vs. &#x0003c; 167)</td><td align="center">1.22</td><td align="center">0.84 to 1.77</td><td align="center">0.290</td><td align="center">1.35</td><td align="center">0.86 to 2.11</td><td align="center">0.189</td><td align="center">1.23</td><td align="center">0.81 to 1.86</td><td align="center">0.34</td></tr><tr><td align="center">D-dimer, ug/L (&#x02265;0.8 vs.&#x02009;&#x0003c;&#x02009;0.8)</td><td align="center">1.60</td><td align="center">1.08 to 2.37</td><td align="center">0.020</td><td align="center">1.79</td><td align="center">1.13 to 2.82</td><td align="center">0.013</td><td align="center">1.58</td><td align="center">1.02 to 2.45</td><td align="center">0.043</td></tr><tr><td align="center">Smoking (yes vs. no)</td><td align="center">1.26</td><td align="center">0.87 to 1.82</td><td align="center">0.216</td><td align="center">1.58</td><td align="center">1.03 to 2.43</td><td align="center">0.036</td><td align="center">1.35</td><td align="center">0.89 to 2.06</td><td align="center">0.159</td></tr></tbody></table><table-wrap-foot><p>
<italic>Abbreviations:</italic>
<italic>ECOG</italic>&#x02009;&#x02009;Eastern Cooperative Oncology Group, <italic>2DRT</italic>&#x02009;&#x02009;two-dimensional radiotherapy, <italic>3DCRT</italic>&#x02009;&#x02009;three-dimensional conformal radiotherapy, <italic>IMRT</italic>&#x02009;&#x02009;intensity-modulated radiotherapy, Low DNA denotes a low EBV DNA level of &#x0003c;4000 copies/ml, High DNA denotes a high EBV DNA level of &#x02265;4000 copies/ml, <italic>LDH</italic>&#x02009;&#x02009;Serum Lactate Dehydrogenase Levels, <italic>CRP</italic>&#x02009;&#x02009;high-sensitivity C-reactive protein, <italic>DFS</italic>&#x02009;&#x02009;disease-free survival, <italic>DMFS</italic>&#x02009;&#x02009;metastasis-free survival, <italic>OS</italic>&#x02009;&#x02009;overall survival.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec13"><title>Prognostic significance of D-dimer within the UICC TNM classification, and patients with high or low EBVDNA level</title><p>Given the independent prognostic significance of elevated D-dimer levels in NPC patients, we evaluated the discrimination power of elevated D-dimer levels in early-stage and advanced-stage patients. Compared to patients with low D-dimer levels, patients with early-stage and advanced-stage disease with elevated D-dimer levels had shorter DFS, DMFS, and OS (Figure&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig3"><label>Figure 3</label><caption><p>
<bold>Kaplan-Meier curves of disease-free survival (A), distant metastasis-free survival (B), and overall survival (C) of NPC patients with early stage (I + II, n = 96), and disease-free survival (D), distant metastasis-free survival (E), and overall survival (F) of NPC patients with advanced stage (III + IV, (n = 621)), according to pre-treatment D-dimer levels.</bold>
</p></caption><graphic xlink:href="12885_2014_5015_Fig3_HTML" id="d30e3003"/></fig></p><p>Consistent with previous reports [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR29">29</xref>], we chose 4000 copies/ml to define the low and high pre-treatment EBVDNA level. In subgroup analysis, patients in the high EBV DNA subgroup with elevated D-dimer levels had a worse DFS, DMFS, and OS compared with the patients with low D-dimer levels. For patients with low EBV DNA levels, there was no difference in DFS, DMFS, and OS between the patients with low or high D-dimer levels (Figure&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>).<fig id="Fig4"><label>Figure 4</label><caption><p>
<bold>Kaplan-Meier curves of disease-free survival (A), distant metastasis-free survival (B), and overall survival (C) of NPC patients with plasma EBV DNA &#x0003c; 4000c copies/ml (n = 411), and disease-free survival (D), distant metastasis-free survival (E), and overall survival (F) of NPC patients with the plasma EBV DNA &#x02265; 4000 copies/ml, according to pre-treatment D-dimer levels.</bold>
</p></caption><graphic xlink:href="12885_2014_5015_Fig4_HTML" id="d30e3026"/></fig></p></sec></sec><sec id="Sec14" sec-type="discussion"><title>Discussion</title><p>To our knowledge, this is the first large-scale cohort study examining the association between coagulation and survival in nasopharyngeal carcinoma patients. The activation of coagulation in cancer patients is widely implicated in both tumour progression and the development of thrombosis [<xref ref-type="bibr" rid="CR31">31</xref>]. High levels of plasma D-dimer have been associated with poor prognosis in several malignant diseases, including lung pancreas, prostate, gastric, colorectal, and breast cancer [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Recently, Liu et al. [<xref ref-type="bibr" rid="CR32">32</xref>] demonstrated that elevated plasma D-dimer was correlated with depth of invasion, lymph node metastasis, peritoneal dissemination, distant metastasis, tumour size, TNM stage, and worse overall survival in gastric cancer. Interestingly, according to our findings, the D-dimer plasma level is a marker of endogenous fibrinolysis that can be used to evaluate hypercoagulability, and it has both clinical and prognostic significance in nasopharyngeal carcinoma patients. With a median follow-up of 3&#x000a0;years, the HR of DFS, DMFS, and OS in cancer patients with the highest D-dimer levels in the total study population (D-dimer levels ranging from 3rd quartile to the maximum level) was two-fold higher than patients with D-dimer levels ranging from the minimum to the 1st quartile. Using the 3rd quartile (0.8&#x000a0;&#x003bc;g/mL) as the final cut-off, multivariate analysis revealed that pre-treatment D-dimer levels were a significant, independent prognostic factor for predicting recurrence, distant metastasis, and death. This effect was independent of EBV DNA level, LDH level, CRP levels, UICC TNM staging, smoking status, and treatment type (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).</p><p>Plasma EBV DNA has been demonstrated to be correlated with tumour burden [<xref ref-type="bibr" rid="CR34">34</xref>], TNM stage [<xref ref-type="bibr" rid="CR35">35</xref>], response to chemoradiotherapy [<xref ref-type="bibr" rid="CR36">36</xref>&#x02013;<xref ref-type="bibr" rid="CR38">38</xref>], and survival in NPC patients [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. Plasma EBV DNA is now a useful biomaker for the clinical management of NPC patients, and it is considered the most attractive potential biomarker [<xref ref-type="bibr" rid="CR37">37</xref>]. However, for NPC patients with EBV DNA &#x02265;4000 copies/ml, patients with D-dimer&#x02009;&#x02265;&#x02009;0.8&#x000a0;&#x003bc;g/L still have a shorter DFS, DMFS, and OS compared to patients with D-dimer&#x02009;&#x0003c;&#x02009;0.8&#x000a0;&#x003bc;g/L. However, this result does not apply to patients with EBV DNA&#x02009;&#x0003c;&#x02009;4000 copies/ml. Although the magnitude of the predictive value of EBV DNA was superior to that of D-dimer, it is not sufficient to use plasma EBV DNA alone for prognostic stratification due to the heterogeneity of NPC patients. Notably, patients in the high EBV DNA subgroup with high plasma D-dimer levels had a worse disease-free survival, distant metastasis-free survival, and overall survival. These results indicate that EBV DNA alone is insufficient to complement the TNM classification, and plasma D-dimer levels represent a complementary marker to EBV DNA leves for the prediction of NPC patient prognosis.</p><p>Although the mechanism underlying D-dimer-mediated NPC progression of remains unknown, it is likely due to different D-dimer signalling pathways or biological behaviours. The association between the D-dimer levels and NPC progression may be explained by abnormalities in haemostasis and fibrinolysis during tumour pathogenesis. The activation of coagulation is the result of increased tissue factor expression, which leads to fibrin deposition. Tumour cells also express tissue factors, and they might contribute to a variety of pathological processes, such as VTE, metastatic spread, tumour growth, and tumour angiogenesis [<xref ref-type="bibr" rid="CR39">39</xref>].</p><p>Interestingly, elevated D-dimer levels still predicted a poorer DFS, DMFS, and OS for early and advanced stage NPC patients in both high and low EBV DNA subgroups, independent of TNM staging (Figure&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). Recent advancements in NPC patient classification and NPC molecular alterations have been made, including microRNA signatures [<xref ref-type="bibr" rid="CR40">40</xref>] and the NPC-SVM classifier [<xref ref-type="bibr" rid="CR41">41</xref>]. However, these developments require expensive and complicated procedures, and rapid clinical implementation was difficult to achieve in a short time. Plasma D-dimer levels are established, routinely measured blood-based parameters that are reproducibly detected without additional laborious efforts before use in clinical applications. These findings have great clinical relevance because D-dimer subgroups with different prognoses in defined TNM stages indicate the need for individual treatment for NPC patients in the future. The association between pre-treatment D-dimer levels and TNM stage may be helpful for screening NPC patients. If a patient displays an abnormally high D-dimer level before treatment, they may require more intensive systemic approaches to improve the treatment outcome.</p><p>However, there are still some limitations to the present study, such as the single D-dimer measurements recorded from a single centre. Another limitation of this study is that we neglected to collect data for venous thromboembolism (VTE) events. High D-dimer levels have previously been reported to predict VTE in cancer patients [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>], and both D-dimer and VTE are negative prognostic factors for cancer patients [<xref ref-type="bibr" rid="CR33">33</xref>]. The third limitation was the short follow-up time, and additional patient data will be reported after the the 5&#x000a0;year follow-up.</p></sec><sec id="Sec15" sec-type="conclusions"><title>Conclusions</title><p>In summary, we demonstrated that pre-treatment D-dimer levels can reflect hypercoagulability in NPC patients. Our results suggest that D-dimer is a promising prognostic biomarker associated with disease-free, distant metastasis-free and overall survival. D-dimers represent a widely available potential biomarker, and the assays to detect D-dimer levels have been sufficiently validated. D-dimers should be considered for routine testing in NPC patients. A prospective study is needed to explore this area, and our results should be validated using other datasets.</p></sec><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><sec id="Sec16"><supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12885_2014_5015_MOESM1_ESM.docx"><caption><p>Additional file 1: Figure S1: Cumulative probability of disease-free survival (DFS), distant metastasis-free survival (DMFS), and overall survival in the total study population (n=717). (1) Patients in the 1st group, with D-dimer levels ranging from minimum to 1st quartile (0.00 to 0.3 &#x003bc;g/mL) levels in the total study population, are compared to (2) those with D-dimer levels in the 2nd group, with levels between the 1st and 2nd quartiles [0.30 to 0.50&#x003bc;g/mL], (3) and those in the 3rd group, with levels between the 2nd and 3rd quartiles [0.50 to 0.80&#x003bc;g/mL], and (4) the 4th group, with D-dimer levels ranging from the 3rd quartile to maximum [0.80to 37.2&#x003bc;g/mL] of D-dimer levels in the study population. The total numbers of patients with D-dimer levels in the 1st, 2nd, 3rd and 4th groups at study institute were 212, 202, 148 and 155, respectively. <bold>Table S1.</bold> D-dimer Relationships. <bold>Table S2.</bold> Prognostic value of D-dimer for DFS, DMFS, and OS by Quartiles. (DOCX 54 KB)</p></caption></media></supplementary-material></sec></sec></body><back><fn-group><fn><p><bold>Competing interests</bold></p><p>We declare that the authors have no competing interest.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>W-HC and L-QT participated in the experimental work, literature research, study design, data collection, data analysis, interpretation of findings and the drafting of the manuscript. F-WW, C-PL, X-PT, X-XH, S-J&#x000a0;M, Y-JL, H-XD, Q-YC, HL, LZ, S-SG, L-TL, J-PZ and S-MY collected blood samples, patient materials and patient follow-up information. X-WL, L-ZL reviewed MR images. C-FL and QL performed statistical analyses. H-QM, M-SZ and DX conceived of and coordinated the study, and critically revised the manuscript. All authors read and approved the final manuscript.</p></fn></fn-group><ack><p>We are grateful to the patients who participated in this study. This study was supported by grants from the Nature Science Foundation of China (No. 81225018, 81172340, 81172939, 81201629 and 81072226), the 863 Project (No: 2012AA02A501), the National Key Basic Research Program of China (No: 2013CB910304), the Sci-Tech Project Foundation of Guangdong Province (No: 2011B080701034, and 2011B031800161), and the Sci-Tech Project Foundation of Guangzhou City (No: 2011&#x000a0;J4300100).</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wee</surname><given-names>JT</given-names></name><name><surname>Ha</surname><given-names>TC</given-names></name><name><surname>Loong</surname><given-names>SL</given-names></name><name><surname>Qian</surname><given-names>CN</given-names></name></person-group><article-title>Is nasopharyngeal cancer really a &#x0201c;Cantonese cancer&#x0201d;?</article-title><source>Chin J Cancer</source><year>2010</year><volume>29</volume><issue>5</issue><fpage>517</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.5732/cjc.009.10329</pub-id><?supplied-pmid 20426903?><pub-id pub-id-type="pmid">20426903</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>ET</given-names></name><name><surname>Adami</surname><given-names>HO</given-names></name></person-group><article-title>The enigmatic epidemiology of nasopharyngeal carcinoma</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2006</year><volume>15</volume><issue>10</issue><fpage>1765</fpage><lpage>1777</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-06-0353</pub-id><?supplied-pmid 17035381?><pub-id pub-id-type="pmid">17035381</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jemal</surname><given-names>A</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Center</surname><given-names>MM</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Ward</surname><given-names>E</given-names></name><name><surname>Forman</surname><given-names>D</given-names></name></person-group><article-title>Global cancer statistics</article-title><source>CA Cancer J Clin</source><year>2011</year><volume>61</volume><issue>2</issue><fpage>69</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.3322/caac.20107</pub-id><?supplied-pmid 21296855?><pub-id pub-id-type="pmid">21296855</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tatsumi-Tamori</surname><given-names>A</given-names></name><name><surname>Yoshizaki</surname><given-names>T</given-names></name><name><surname>Miwa</surname><given-names>T</given-names></name><name><surname>Furukawa</surname><given-names>M</given-names></name></person-group><article-title>Clinical evaluation of staging system for nasopharyngeal carcinoma: comparison of fourth and fifth editions of UICC TNM classification</article-title><source>Ann Otol Rhinol Laryngol</source><year>2000</year><volume>109</volume><issue>12 Pt 1</issue><fpage>1125</fpage><lpage>1129</lpage><pub-id pub-id-type="doi">10.1177/000348940010901208</pub-id><?supplied-pmid 11130824?><pub-id pub-id-type="pmid">11130824</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chua</surname><given-names>DT</given-names></name><name><surname>Nicholls</surname><given-names>JM</given-names></name><name><surname>Sham</surname><given-names>JS</given-names></name><name><surname>Au</surname><given-names>GK</given-names></name></person-group><article-title>Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2004</year><volume>59</volume><issue>1</issue><fpage>11</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2003.10.038</pub-id><?supplied-pmid 15093894?><pub-id pub-id-type="pmid">15093894</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>GQ</given-names></name><name><surname>Tang</surname><given-names>LL</given-names></name><name><surname>Mao</surname><given-names>YP</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>WF</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>LZ</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Lin</surname><given-names>AH</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name></person-group><article-title>Baseline serum lactate dehydrogenase levels for patients treated with intensity-modulated radiotherapy for nasopharyngeal carcinoma: a predictor of poor prognosis and subsequent liver metastasis</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2012</year><volume>82</volume><issue>3</issue><fpage>e359</fpage><lpage>e365</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2011.06.1967</pub-id><?supplied-pmid 22000748?><pub-id pub-id-type="pmid">22000748</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>WX</given-names></name><name><surname>Zhang</surname><given-names>HB</given-names></name><name><surname>Shi</surname><given-names>JL</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Ye</surname><given-names>YF</given-names></name><name><surname>Cao</surname><given-names>KJ</given-names></name><name><surname>Qian</surname><given-names>CN</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Xiang</surname><given-names>YQ</given-names></name></person-group><article-title>A prognostic model predicts the risk of distant metastasis and death for patients with nasopharyngeal carcinoma based on pre-treatment serum C-reactive protein and N-classification</article-title><source>Eur J Cancer</source><year>2013</year><volume>49</volume><issue>9</issue><fpage>2152</fpage><lpage>2160</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2013.03.003</pub-id><?supplied-pmid 23571148?><pub-id pub-id-type="pmid">23571148</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>JC</given-names></name><name><surname>Wang</surname><given-names>WY</given-names></name><name><surname>Chen</surname><given-names>KY</given-names></name><name><surname>Wei</surname><given-names>YH</given-names></name><name><surname>Liang</surname><given-names>WM</given-names></name><name><surname>Jan</surname><given-names>JS</given-names></name><name><surname>Jiang</surname><given-names>RS</given-names></name></person-group><article-title>Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma</article-title><source>N Engl J Med</source><year>2004</year><volume>350</volume><issue>24</issue><fpage>2461</fpage><lpage>2470</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa032260</pub-id><?supplied-pmid 15190138?><pub-id pub-id-type="pmid">15190138</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>SF</given-names></name><name><surname>Chan</surname><given-names>AT</given-names></name><name><surname>Zee</surname><given-names>B</given-names></name><name><surname>Ma</surname><given-names>B</given-names></name><name><surname>Chan</surname><given-names>LY</given-names></name><name><surname>Johnson</surname><given-names>PJ</given-names></name><name><surname>Lo</surname><given-names>YM</given-names></name></person-group><article-title>Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type</article-title><source>Cancer</source><year>2003</year><volume>98</volume><issue>2</issue><fpage>288</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1002/cncr.11496</pub-id><?supplied-pmid 12872347?><pub-id pub-id-type="pmid">12872347</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>SF</given-names></name><name><surname>Zee</surname><given-names>B</given-names></name><name><surname>Ma</surname><given-names>BB</given-names></name><name><surname>Hui</surname><given-names>EP</given-names></name><name><surname>Mo</surname><given-names>F</given-names></name><name><surname>Lai</surname><given-names>M</given-names></name><name><surname>Chan</surname><given-names>KC</given-names></name><name><surname>Chan</surname><given-names>LY</given-names></name><name><surname>Kwan</surname><given-names>WH</given-names></name><name><surname>Lo</surname><given-names>YM</given-names></name><name><surname>Chan</surname><given-names>AT</given-names></name></person-group><article-title>Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><issue>34</issue><fpage>5414</fpage><lpage>5418</lpage><pub-id pub-id-type="doi">10.1200/JCO.2006.07.7982</pub-id><?supplied-pmid 17135642?><pub-id pub-id-type="pmid">17135642</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyman</surname><given-names>GH</given-names></name><name><surname>Khorana</surname><given-names>AA</given-names></name></person-group><article-title>Cancer, clots and consensus: new understanding of an old problem</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><issue>29</issue><fpage>4821</fpage><lpage>4826</lpage><pub-id pub-id-type="doi">10.1200/JCO.2009.22.3032</pub-id><?supplied-pmid 19752337?><pub-id pub-id-type="pmid">19752337</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beer</surname><given-names>JH</given-names></name><name><surname>Haeberli</surname><given-names>A</given-names></name><name><surname>Vogt</surname><given-names>A</given-names></name><name><surname>Woodtli</surname><given-names>K</given-names></name><name><surname>Henkel</surname><given-names>E</given-names></name><name><surname>Furrer</surname><given-names>T</given-names></name><name><surname>Fey</surname><given-names>MF</given-names></name></person-group><article-title>Coagulation markers predict survival in cancer patients</article-title><source>Thromb Haemost</source><year>2002</year><volume>88</volume><issue>5</issue><fpage>745</fpage><lpage>749</lpage><?supplied-pmid 12428088?><pub-id pub-id-type="pmid">12428088</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>RL</given-names></name><name><surname>Rickles</surname><given-names>FR</given-names></name><name><surname>Moritz</surname><given-names>TE</given-names></name><name><surname>Henderson</surname><given-names>WG</given-names></name><name><surname>Zacharski</surname><given-names>LR</given-names></name><name><surname>Forman</surname><given-names>WB</given-names></name><name><surname>Cornell</surname><given-names>CJ</given-names></name><name><surname>Forcier</surname><given-names>RJ</given-names></name><name><surname>O&#x02019;Donnell</surname><given-names>JF</given-names></name><name><surname>Headley</surname><given-names>E</given-names></name></person-group><article-title>Abnormalities of blood coagulation tests in patients with cancer</article-title><source>Am J Clin Pathol</source><year>1987</year><volume>88</volume><issue>5</issue><fpage>596</fpage><lpage>602</lpage><?supplied-pmid 3673941?><pub-id pub-id-type="pmid">3673941</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falanga</surname><given-names>A</given-names></name><name><surname>Panova-Noeva</surname><given-names>M</given-names></name><name><surname>Russo</surname><given-names>L</given-names></name></person-group><article-title>Procoagulant mechanisms in tumour cells</article-title><source>Best Pract Res Clin Haematol</source><year>2009</year><volume>22</volume><issue>1</issue><fpage>49</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.beha.2008.12.009</pub-id><?supplied-pmid 19285272?><pub-id pub-id-type="pmid">19285272</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lippi</surname><given-names>G</given-names></name><name><surname>Franchini</surname><given-names>M</given-names></name><name><surname>Biasiutti</surname><given-names>C</given-names></name><name><surname>Dellagiacoma</surname><given-names>G</given-names></name><name><surname>Salvagno</surname><given-names>GL</given-names></name><name><surname>Guidi</surname><given-names>GC</given-names></name></person-group><article-title>Increased D-dimer value and occult cancer in the absence of detectable thrombosis</article-title><source>Haematologica</source><year>2007</year><volume>92</volume><issue>4</issue><fpage>e53</fpage><lpage>e55</lpage><pub-id pub-id-type="doi">10.3324/haematol.12237</pub-id><?supplied-pmid 17562593?><pub-id pub-id-type="pmid">17562593</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>JC</given-names></name></person-group><article-title>Coagulation and cancer</article-title><source>Br J Cancer</source><year>1991</year><volume>64</volume><issue>3</issue><fpage>422</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1038/bjc.1991.325</pub-id><?supplied-pmid 1911180?><pub-id pub-id-type="pmid">1911180</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alcalay</surname><given-names>A</given-names></name><name><surname>Wun</surname><given-names>T</given-names></name><name><surname>Khatri</surname><given-names>V</given-names></name><name><surname>Chew</surname><given-names>HK</given-names></name><name><surname>Harvey</surname><given-names>D</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>White</surname><given-names>RH</given-names></name></person-group><article-title>Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><issue>7</issue><fpage>1112</fpage><lpage>1118</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.04.2150</pub-id><?supplied-pmid 16505431?><pub-id pub-id-type="pmid">16505431</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batschauer</surname><given-names>AP</given-names></name><name><surname>Figueiredo</surname><given-names>CP</given-names></name><name><surname>Bueno</surname><given-names>EC</given-names></name><name><surname>Ribeiro</surname><given-names>MA</given-names></name><name><surname>Dusse</surname><given-names>LM</given-names></name><name><surname>Fernandes</surname><given-names>AP</given-names></name><name><surname>Gomes</surname><given-names>KB</given-names></name><name><surname>Carvalho</surname><given-names>MG</given-names></name></person-group><article-title>D-dimer as a possible prognostic marker of operable hormone receptor-negative breast cancer</article-title><source>Ann Oncol</source><year>2010</year><volume>21</volume><issue>6</issue><fpage>1267</fpage><lpage>1272</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdp474</pub-id><?supplied-pmid 19880435?><pub-id pub-id-type="pmid">19880435</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blackwell</surname><given-names>K</given-names></name><name><surname>Hurwitz</surname><given-names>H</given-names></name><name><surname>Lieberman</surname><given-names>G</given-names></name><name><surname>Novotny</surname><given-names>W</given-names></name><name><surname>Snyder</surname><given-names>S</given-names></name><name><surname>Dewhirst</surname><given-names>M</given-names></name><name><surname>Greenberg</surname><given-names>C</given-names></name></person-group><article-title>Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma</article-title><source>Cancer</source><year>2004</year><volume>101</volume><issue>1</issue><fpage>77</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1002/cncr.20336</pub-id><?supplied-pmid 15221991?><pub-id pub-id-type="pmid">15221991</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buccheri</surname><given-names>G</given-names></name><name><surname>Torchio</surname><given-names>P</given-names></name><name><surname>Ferrigno</surname><given-names>D</given-names></name></person-group><article-title>Plasma levels of D-dimer in lung carcinoma: clinical and prognostic significance</article-title><source>Cancer</source><year>2003</year><volume>97</volume><issue>12</issue><fpage>3044</fpage><lpage>3052</lpage><pub-id pub-id-type="doi">10.1002/cncr.11432</pub-id><?supplied-pmid 12784340?><pub-id pub-id-type="pmid">12784340</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakashima</surname><given-names>J</given-names></name><name><surname>Tachibana</surname><given-names>M</given-names></name><name><surname>Ueno</surname><given-names>M</given-names></name><name><surname>Baba</surname><given-names>S</given-names></name><name><surname>Tazaki</surname><given-names>H</given-names></name></person-group><article-title>Tumor necrosis factor and coagulopathy in patients with prostate cancer</article-title><source>Cancer Res</source><year>1995</year><volume>55</volume><issue>21</issue><fpage>4881</fpage><lpage>4885</lpage><?supplied-pmid 7585524?><pub-id pub-id-type="pmid">7585524</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Han</surname><given-names>F</given-names></name><name><surname>Lu</surname><given-names>LX</given-names></name><name><surname>Huang</surname><given-names>SM</given-names></name><name><surname>Lin</surname><given-names>CG</given-names></name><name><surname>Deng</surname><given-names>XW</given-names></name><name><surname>Lu</surname><given-names>TX</given-names></name><name><surname>Cui</surname><given-names>NJ</given-names></name></person-group><article-title>[Intensity modulated radiotherapy for local-regional advanced nasopharyngeal carcinoma]</article-title><source>Ai Zheng</source><year>2004</year><volume>23</volume><issue>11 Suppl</issue><fpage>1532</fpage><lpage>1537</lpage><?supplied-pmid 15566674?><pub-id pub-id-type="pmid">15566674</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Tang</surname><given-names>L</given-names></name><name><surname>Zong</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>A</given-names></name><name><surname>Lu</surname><given-names>T</given-names></name><name><surname>Cui</surname><given-names>N</given-names></name><name><surname>Cui</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>L</given-names></name></person-group><article-title>Retropharyngeal lymph node metastasis in nasopharyngeal carcinoma: prognostic value and staging categories</article-title><source>Clin Cancer Res</source><year>2007</year><volume>13</volume><issue>5</issue><fpage>1445</fpage><lpage>1452</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-2059</pub-id><?supplied-pmid 17332287?><pub-id pub-id-type="pmid">17332287</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>QY</given-names></name><name><surname>Wen</surname><given-names>YF</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>PY</given-names></name><name><surname>Mo</surname><given-names>HY</given-names></name><name><surname>Li</surname><given-names>NW</given-names></name><name><surname>Xiang</surname><given-names>YQ</given-names></name><name><surname>Luo</surname><given-names>DH</given-names></name><name><surname>Qiu</surname><given-names>F</given-names></name><name><surname>Sun</surname><given-names>R</given-names></name><name><surname>Deng</surname><given-names>MQ</given-names></name><name><surname>Chen</surname><given-names>MY</given-names></name><name><surname>Hua</surname><given-names>YJ</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Cao</surname><given-names>KJ</given-names></name><name><surname>Hong</surname><given-names>MH</given-names></name><name><surname>Qian</surname><given-names>CN</given-names></name><name><surname>Mai</surname><given-names>HQ</given-names></name></person-group><article-title>Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial</article-title><source>J Natl Cancer Inst</source><year>2011</year><volume>103</volume><issue>23</issue><fpage>1761</fpage><lpage>1770</lpage><pub-id pub-id-type="doi">10.1093/jnci/djr432</pub-id><?supplied-pmid 22056739?><pub-id pub-id-type="pmid">22056739</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Hu</surname><given-names>CS</given-names></name><name><surname>Chen</surname><given-names>XZ</given-names></name><name><surname>Hu</surname><given-names>GQ</given-names></name><name><surname>Cheng</surname><given-names>ZB</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>WX</given-names></name><name><surname>Chen</surname><given-names>YY</given-names></name><name><surname>Xie</surname><given-names>FY</given-names></name><name><surname>Liang</surname><given-names>SB</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>TT</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Long</surname><given-names>GX</given-names></name><name><surname>Wang</surname><given-names>SY</given-names></name><name><surname>Zheng</surname><given-names>BM</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Mao</surname><given-names>YP</given-names></name><name><surname>Tang</surname><given-names>LL</given-names></name><name><surname>Chen</surname><given-names>YM</given-names></name><name><surname>Liu</surname><given-names>MZ</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name></person-group><article-title>Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial</article-title><source>Lancet Oncol</source><year>2012</year><volume>13</volume><issue>2</issue><fpage>163</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(11)70320-5</pub-id><?supplied-pmid 22154591?><pub-id pub-id-type="pmid">22154591</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lo</surname><given-names>YM</given-names></name><name><surname>Chan</surname><given-names>LY</given-names></name><name><surname>Lo</surname><given-names>KW</given-names></name><name><surname>Leung</surname><given-names>SF</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Chan</surname><given-names>AT</given-names></name><name><surname>Lee</surname><given-names>JC</given-names></name><name><surname>Hjelm</surname><given-names>NM</given-names></name><name><surname>Johnson</surname><given-names>PJ</given-names></name><name><surname>Huang</surname><given-names>DP</given-names></name></person-group><article-title>Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma</article-title><source>Cancer Res</source><year>1999</year><volume>59</volume><issue>6</issue><fpage>1188</fpage><lpage>1191</lpage><?supplied-pmid 10096545?><pub-id pub-id-type="pmid">10096545</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shao</surname><given-names>JY</given-names></name><name><surname>Li</surname><given-names>YH</given-names></name><name><surname>Gao</surname><given-names>HY</given-names></name><name><surname>Wu</surname><given-names>QL</given-names></name><name><surname>Cui</surname><given-names>NJ</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Cheng</surname><given-names>G</given-names></name><name><surname>Hu</surname><given-names>LF</given-names></name><name><surname>Ernberg</surname><given-names>I</given-names></name><name><surname>Zeng</surname><given-names>YX</given-names></name></person-group><article-title>Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma</article-title><source>Cancer</source><year>2004</year><volume>100</volume><issue>6</issue><fpage>1162</fpage><lpage>1170</lpage><pub-id pub-id-type="doi">10.1002/cncr.20099</pub-id><?supplied-pmid 15022282?><pub-id pub-id-type="pmid">15022282</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>An</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>FH</given-names></name><name><surname>Ding</surname><given-names>PR</given-names></name><name><surname>Deng</surname><given-names>L</given-names></name><name><surname>Jiang</surname><given-names>WQ</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Shao</surname><given-names>JY</given-names></name><name><surname>Li</surname><given-names>YH</given-names></name></person-group><article-title>Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy</article-title><source>Cancer</source><year>2011</year><volume>117</volume><issue>16</issue><fpage>3750</fpage><lpage>3757</lpage><pub-id pub-id-type="doi">10.1002/cncr.25932</pub-id><?supplied-pmid 21319149?><pub-id pub-id-type="pmid">21319149</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>AT</given-names></name><name><surname>Lo</surname><given-names>YM</given-names></name><name><surname>Zee</surname><given-names>B</given-names></name><name><surname>Chan</surname><given-names>LY</given-names></name><name><surname>Ma</surname><given-names>BB</given-names></name><name><surname>Leung</surname><given-names>SF</given-names></name><name><surname>Mo</surname><given-names>F</given-names></name><name><surname>Lai</surname><given-names>M</given-names></name><name><surname>Ho</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>DP</given-names></name><name><surname>Johnson</surname><given-names>PJ</given-names></name></person-group><article-title>Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma</article-title><source>J Natl Cancer Inst</source><year>2002</year><volume>94</volume><issue>21</issue><fpage>1614</fpage><lpage>1619</lpage><pub-id pub-id-type="doi">10.1093/jnci/94.21.1614</pub-id><?supplied-pmid 12419787?><pub-id pub-id-type="pmid">12419787</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Jia</surname><given-names>W</given-names></name><name><surname>Chang</surname><given-names>E</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Mo</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Rao</surname><given-names>D</given-names></name><name><surname>Ye</surname><given-names>W</given-names></name><name><surname>Cao</surname><given-names>S</given-names></name><name><surname>Hong</surname><given-names>M</given-names></name></person-group><article-title>Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China</article-title><source>Int J Cancer</source><year>2012</year><volume>131</volume><issue>2</issue><fpage>406</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1002/ijc.26380</pub-id><?supplied-pmid 21866545?><pub-id pub-id-type="pmid">21866545</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franchini</surname><given-names>M</given-names></name><name><surname>Montagnana</surname><given-names>M</given-names></name><name><surname>Targher</surname><given-names>G</given-names></name><name><surname>Manzato</surname><given-names>F</given-names></name><name><surname>Lippi</surname><given-names>G</given-names></name></person-group><article-title>Pathogenesis, clinical and laboratory aspects of thrombosis in cancer</article-title><source>J Thromb Thrombolysis</source><year>2007</year><volume>24</volume><issue>1</issue><fpage>29</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1007/s11239-007-0028-6</pub-id><?supplied-pmid 17396228?><pub-id pub-id-type="pmid">17396228</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Yan</surname><given-names>B</given-names></name><name><surname>Gu</surname><given-names>Q</given-names></name><name><surname>Jiao</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Yue</surname><given-names>X</given-names></name></person-group><article-title>Elevated plasma D-dimer levels correlate with long term survival of gastric cancer patients</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><issue>3</issue><fpage>e90547</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0090547</pub-id><?supplied-pmid 24618826?><pub-id pub-id-type="pmid">24618826</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ay</surname><given-names>C</given-names></name><name><surname>Dunkler</surname><given-names>D</given-names></name><name><surname>Pirker</surname><given-names>R</given-names></name><name><surname>Thaler</surname><given-names>J</given-names></name><name><surname>Quehenberger</surname><given-names>P</given-names></name><name><surname>Wagner</surname><given-names>O</given-names></name><name><surname>Zielinski</surname><given-names>C</given-names></name><name><surname>Pabinger</surname><given-names>I</given-names></name></person-group><article-title>High D-dimer levels are associated with poor prognosis in cancer patients</article-title><source>Haematologica</source><year>2012</year><volume>97</volume><issue>8</issue><fpage>1158</fpage><lpage>1164</lpage><pub-id pub-id-type="doi">10.3324/haematol.2011.054718</pub-id><?supplied-pmid 22371182?><pub-id pub-id-type="pmid">22371182</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>BB</given-names></name><name><surname>King</surname><given-names>A</given-names></name><name><surname>Lo</surname><given-names>YM</given-names></name><name><surname>Yau</surname><given-names>YY</given-names></name><name><surname>Zee</surname><given-names>B</given-names></name><name><surname>Hui</surname><given-names>EP</given-names></name><name><surname>Leung</surname><given-names>SF</given-names></name><name><surname>Mo</surname><given-names>F</given-names></name><name><surname>Kam</surname><given-names>MK</given-names></name><name><surname>Ahuja</surname><given-names>A</given-names></name><name><surname>Kwan</surname><given-names>WH</given-names></name><name><surname>Chan</surname><given-names>AT</given-names></name></person-group><article-title>Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma</article-title><source>Int J Radiat Oncol Biol Phys</source><year>2006</year><volume>66</volume><issue>3</issue><fpage>714</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2006.05.064</pub-id><?supplied-pmid 17011447?><pub-id pub-id-type="pmid">17011447</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lo</surname><given-names>YM</given-names></name><name><surname>Leung</surname><given-names>SF</given-names></name><name><surname>Chan</surname><given-names>LY</given-names></name><name><surname>Lo</surname><given-names>KW</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Chan</surname><given-names>AT</given-names></name><name><surname>Lee</surname><given-names>JC</given-names></name><name><surname>Hjelm</surname><given-names>NM</given-names></name><name><surname>Johnson</surname><given-names>PJ</given-names></name><name><surname>Huang</surname><given-names>DP</given-names></name></person-group><article-title>Plasma cell-free Epstein-Barr virus DNA quantitation in patients with nasopharyngeal carcinoma. Correlation with clinical staging</article-title><source>Ann N Y Acad Sci</source><year>2000</year><volume>906</volume><fpage>99</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2000.tb06597.x</pub-id><?supplied-pmid 10818603?><pub-id pub-id-type="pmid">10818603</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lo</surname><given-names>YM</given-names></name><name><surname>Chan</surname><given-names>LY</given-names></name><name><surname>Chan</surname><given-names>AT</given-names></name><name><surname>Leung</surname><given-names>SF</given-names></name><name><surname>Lo</surname><given-names>KW</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>JC</given-names></name><name><surname>Hjelm</surname><given-names>NM</given-names></name><name><surname>Johnson</surname><given-names>PJ</given-names></name><name><surname>Huang</surname><given-names>DP</given-names></name></person-group><article-title>Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma</article-title><source>Cancer Res</source><year>1999</year><volume>59</volume><issue>21</issue><fpage>5452</fpage><lpage>5455</lpage><?supplied-pmid 10554016?><pub-id pub-id-type="pmid">10554016</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name></person-group><article-title>A meta-analysis on the EBV DNA and VCA-IgA in diagnosis of Nasopharyngeal Carcinoma</article-title><source>Pak J Med Sci</source><year>2013</year><volume>29</volume><issue>3</issue><fpage>885</fpage><lpage>890</lpage><?supplied-pmid 24353651?><pub-id pub-id-type="pmid">24353651</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>SF</given-names></name><name><surname>Chan</surname><given-names>KC</given-names></name><name><surname>Ma</surname><given-names>BB</given-names></name><name><surname>Hui</surname><given-names>EP</given-names></name><name><surname>Mo</surname><given-names>F</given-names></name><name><surname>Chow</surname><given-names>KC</given-names></name><name><surname>Leung</surname><given-names>L</given-names></name><name><surname>Chu</surname><given-names>KW</given-names></name><name><surname>Zee</surname><given-names>B</given-names></name><name><surname>Lo</surname><given-names>YM</given-names></name><name><surname>Chan</surname><given-names>AT</given-names></name></person-group><article-title>Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma</article-title><source>Ann Oncol</source><year>2014</year><volume>25</volume><issue>6</issue><fpage>1204</fpage><lpage>1208</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdu117</pub-id><?supplied-pmid 24638904?><pub-id pub-id-type="pmid">24638904</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasthuri</surname><given-names>RS</given-names></name><name><surname>Taubman</surname><given-names>MB</given-names></name><name><surname>Mackman</surname><given-names>N</given-names></name></person-group><article-title>Role of tissue factor in cancer</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><issue>29</issue><fpage>4834</fpage><lpage>4838</lpage><pub-id pub-id-type="doi">10.1200/JCO.2009.22.6324</pub-id><?supplied-pmid 19738116?><pub-id pub-id-type="pmid">19738116</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>NY</given-names></name><name><surname>Cui</surname><given-names>RX</given-names></name><name><surname>Li</surname><given-names>WF</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>RR</given-names></name><name><surname>Zhang</surname><given-names>MY</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>BJ</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>He</surname><given-names>QM</given-names></name><name><surname>Jiang</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Cho</surname><given-names>WC</given-names></name><name><surname>Yun</surname><given-names>JP</given-names></name><name><surname>Zeng</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>LZ</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>HY</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name></person-group><article-title>Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis</article-title><source>Lancet Oncol</source><year>2012</year><volume>13</volume><issue>6</issue><fpage>633</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(12)70102-X</pub-id><?supplied-pmid 22560814?><pub-id pub-id-type="pmid">22560814</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>HY</given-names></name><name><surname>Sun</surname><given-names>BY</given-names></name><name><surname>Zhu</surname><given-names>ZH</given-names></name><name><surname>Chang</surname><given-names>ET</given-names></name><name><surname>To</surname><given-names>KF</given-names></name><name><surname>Hwang</surname><given-names>JS</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Kam</surname><given-names>MK</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Cheah</surname><given-names>SL</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>ZW</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>JX</given-names></name><name><surname>Zhang</surname><given-names>HZ</given-names></name><name><surname>He</surname><given-names>JH</given-names></name><name><surname>Chen</surname><given-names>FL</given-names></name><name><surname>Zhu</surname><given-names>XD</given-names></name><name><surname>Huang</surname><given-names>MY</given-names></name><name><surname>Liao</surname><given-names>DZ</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Shao</surname><given-names>Q</given-names></name><name><surname>Cai</surname><given-names>MB</given-names></name><name><surname>Du</surname><given-names>ZM</given-names></name><name><surname>Yan</surname><given-names>LX</given-names></name><name><surname>Hu</surname><given-names>CF</given-names></name><name><surname>Ng</surname><given-names>HK</given-names></name><name><surname>Wee</surname><given-names>JT</given-names></name><name><surname>Qian</surname><given-names>CN</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Eight-signature classifier for prediction of nasopharyngeal [corrected] carcinoma survival</article-title><source>J Clin Oncol</source><year>2011</year><volume>29</volume><issue>34</issue><fpage>4516</fpage><lpage>4525</lpage><pub-id pub-id-type="doi">10.1200/JCO.2010.33.7741</pub-id><?supplied-pmid 22025164?><pub-id pub-id-type="pmid">22025164</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ay</surname><given-names>C</given-names></name><name><surname>Vormittag</surname><given-names>R</given-names></name><name><surname>Dunkler</surname><given-names>D</given-names></name><name><surname>Simanek</surname><given-names>R</given-names></name><name><surname>Chiriac</surname><given-names>AL</given-names></name><name><surname>Drach</surname><given-names>J</given-names></name><name><surname>Quehenberger</surname><given-names>P</given-names></name><name><surname>Wagner</surname><given-names>O</given-names></name><name><surname>Zielinski</surname><given-names>C</given-names></name><name><surname>Pabinger</surname><given-names>I</given-names></name></person-group><article-title>D-dimer and prothrombin fragment 1&#x02009;+&#x02009;2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><issue>25</issue><fpage>4124</fpage><lpage>4129</lpage><pub-id pub-id-type="doi">10.1200/JCO.2008.21.7752</pub-id><?supplied-pmid 19636003?><pub-id pub-id-type="pmid">19636003</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arpaia</surname><given-names>G</given-names></name><name><surname>Carpenedo</surname><given-names>M</given-names></name><name><surname>Verga</surname><given-names>M</given-names></name><name><surname>Mastrogiacomo</surname><given-names>O</given-names></name><name><surname>Fagnani</surname><given-names>D</given-names></name><name><surname>Lanfredini</surname><given-names>M</given-names></name><name><surname>Milani</surname><given-names>M</given-names></name><name><surname>Cimminiello</surname><given-names>C</given-names></name></person-group><article-title>D-dimer before chemotherapy might predict venous thromboembolism</article-title><source>Blood Coagul Fibrinolysis</source><year>2009</year><volume>20</volume><issue>3</issue><fpage>170</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1097/MBC.0b013e32831bc2de</pub-id><?supplied-pmid 19276795?><pub-id pub-id-type="pmid">19276795</pub-id></element-citation></ref><ref-list id="BSec1"><title>Pre-publication history</title><ref id="CR44"><mixed-citation publication-type="other">The pre-publication history for this paper can be accessed here:
<ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/14/583/prepub">http://www.biomedcentral.com/1471-2407/14/583/prepub</ext-link></mixed-citation></ref></ref-list></ref-list></back></article>
